Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05030038 · ClinicalTrials.gov registry record
Oral Aromatase Inhibitors Modify the Gut Microbiome
A clinical trial of Breast Cancer, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- 25
- Enrollment target
- 1
- Study location
NCT05030038 is a study of Breast Cancer that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 25 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05030038, a study of Breast Cancer, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to study the bacteria in participants' gut before receiving a medicine called an aromatase inhibitor for breast cancer and after participants receive medicine for breast cancer.
Conditions Studied
Interventions
- BIOLOGICAL Fecal swab collection
- BIOLOGICAL Blood samples
Study Locations (1)
North Carolina
- Wake Forest Baptist Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-03-29 |
| Est. Completion | 2026-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05030038
The ClinicalTrials.gov registry entry for NCT05030038 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Fecal swab collection is the first listed.
NCT05030038 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05030038 about?
NCT05030038 is a clinical study titled "Oral Aromatase Inhibitors Modify the Gut Microbiome". The purpose of this research is to study the bacteria in participants' gut before receiving a medicine called an aromatase inhibitor for breast cancer and after participants receive medicine for breast cancer.
What is the current status of trial NCT05030038?
This trial is currently recruiting. The enrollment target is 25 participants. The study started on 2022-03-29. Estimated completion is 2026-05.
What conditions does trial NCT05030038 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT05030038?
The interventions under investigation include: Fecal swab collection (BIOLOGICAL), Blood samples (BIOLOGICAL).
Who is sponsoring clinical trial NCT05030038?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05030038 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.